Moreover, the effective dosage of CD47 antagonists may require adjustments in scenarios where tumor cells express both SIRPα and thrombospondin-1 (TSP-1), both of which disrupt the CD47-SIRPα interaction. The gene discussed is SIRPA; the disease is neoplasm.